OVER / UNDER
KXFDAAPPROVE-CAG ★ KALSHI ★ MULTI ★ KXFDAAPPROVE-CAG ★ KALSHI ★ MULTI ★ KXFDAAPPROVE-CAG ★ KALSHI ★ MULTI ★ KXFDAAPPROVE-CAG ★ KALSHI ★ MULTI ★ KXFDAAPPROVE-CAG ★ KALSHI ★ MULTI ★ KXFDAAPPROVE-CAG ★ KALSHI ★ MULTI ★

Will the FDA approve CagriSema?

Price history — Before Jul 1, 2027

Last 7 days of market YES price (blue) with the fair-price range (orange).

81¢0¢25¢50¢75¢100¢Tue 5/19Wed 5/20Thu 5/21Fri 5/22Sat 5/23Sun 5/24TODAY
━ market YES▬ fair range
Market price
Before Jul 1, 2027★ BEST81¢
Before Jan 1, 202770¢
Before Jan 1, 202860¢
Before Oct 1, 202635¢
Before Jul 1, 202622¢
Kalshi • Volume: 1.9K contracts • Updated 4h agoCloses: 2028-01-01
Kalshi · Science and Technology
OU's Pick
YES · Before Jul 1, 2027
at 81¢
Price gap
Kalshi81¢
→
OU's fair75¢
−6¢ overpriced · pays 1.2×
Confidence
Moderate

Novo Nordisk has filed for FDA approval with a review expected in late 2026 or early 2027 based on standard ten to twelve month regulatory timelines.

Not financial advice. For informational purposes only. Prediction markets involve risk of loss. AI may contain errors.